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Several oxindole derivatives, of natural or synthetic origin, have been identified as medicinally appealing
compounds, with a plethora of bioactivities reported. Chiral 3-hydroxy and 3-aminooxindole scaffolds
have captured the attention of several research groups, due to their importance in drug discovery. In this
review, we systematically address the wide variety of asymmetric catalytic methodologies employed in
the preparation of these relevant chiral scaffolds, present in many biologically active compounds and/or
natural products. Special focus will be given to the nature of the catalyst used.
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The oxindole scaffold (chemically named 1,3-dihydro-2H-
indole-2-one) is a valuable motif in several fields of Chemistry, but
particularly in Organic Chemistry and Medicinal Chemistry, since it
is present in a wide variety of natural products and synthetic
compounds that present interesting bioactivities [1]. The presence
of stereocenters can be crucial for the bioactivity, pharmacokinetic
profile and even environmental impact of molecules with inter-
esting medicinal applications [2e5].
From the synthetic point of view, the preparation of chiral
bioactive compounds, from new molecular entities to the total
synthesis of known natural products, can be quite challenging to
organic chemists. Enantiomeric separation of racemic mixtures or
kinetic resolution many times is not desired nor profitable and thus
asymmetric synthesis became the focus for many research groups
involved in organic synthesis and medicinal chemistry [6,7].
Asymmetric catalytic methods, namely those based on the use of
chiral organocatalysts or chiral metal-based complexes to prepare
molecules in the enantiomerically pure form has become a recur-
rent topic in the scientific literature [8e10]. In the current litera-
ture, we found reports of 3-hydroxy-oxindoles showing a plethora
of potential medicinal applications, including anti-tumor [11e13],
monoamine oxidase inhibition [14], anti-HIV [15], antioxidant
[16,17] and antimicrobial activities [17]. Some of these reactions
were conducted using green synthetic methods, but without any
chiral catalysts. However, further studies are required to determine
the impact of the configuration of its stereogenic center on the
bioactivity of these molecules.
Due to the relevance of the oxindole scaffold in Medicinal
Chemistry and the bioactivity presented by several chiral 3,3-
disubstituted-oxindole derivatives, several recent review publica-
tions have appeared in the literature, that range from the bioac-
tivity of chiral spirooxindole compounds [18,19] to the asymmetric
catalytic preparation of chiral 3,3-disubstituted-oxindole de-
rivatives [20e24]. Indolin-2,3-dione, commonly known as isatin, is
quite often used as starting material for such synthetic modifica-
tions [25e29]. Natural and synthetic spirooxindoles are of major
interest in the fields of Organic and Medicinal Chemistry due to
their wide range of biological applications [30e36]. However, there
is very little focus on this family of oxindoles in this review,
particularly as their asymmetric catalytic synthesis was recently
comprehensively reviewed [37].
In this review, attention will be given to the current state of the
art of the asymmetric synthesis of 3-hydroxy and 3-aminooxindole
derivatives. Since there are several reviews published on the type of
reaction for the synthesis of these compounds [38e41], we decided
to organize this review according to the type of catalyst used.
Furthermore, in this review we explore the synthesis of 3-hydroxy
and 3-aminooxindole derivatives that have or exhibit potential
medicinal properties and that have appeared in the literature over
the last 10 years.2. 3ehydroxyoxindole derivatives
Nature has been the source of biologically active compounds for
millenia, many of them bearing one or more stereocenters. Among
these, some chiral 3-hydroxy-oxindole derivatives surfaced as
relevantmolecules in the field of Medicinal Chemistry (Fig.1). TMC-
95A, isolated from the ascomycete fungus Apiospora montagnei,
presented 20S proteasome inhibition activity [42,43]. Another
natural product, 3-hydroxy-N-methylwelwitindolinone C isothio-
cyanate, identified in marine cyanobacteria, belongs to a family of
alkaloids with a broad spectrum of biological activities, including
antifungal, insecticidal, and antitumor, due to its ability to inhibit
multidrug resistance targets and tubulin polymerization [44e46].
Maremycins are a group of compounds isolated from Streptomyces
sp. bearing the 3-substituted-3-hydroxy-2-oxindole structural
motif. Maremycins B and C present slight cytotoxicity towards
some tumor cell lines [47]. The total synthesis of this group of
compounds and their derivatives remains a very interesting chal-
lenge for organic and medicinal chemists, as we will see later on in
this review.
In the case of maremycins, although the total syntheses of these
compounds have been described in the literature, in most cases a
diastereoselective protocol was investigated with no asymmetric
catalysis. An exception is the synthesis of maremycin A reported by
Bergonzini and Melchiore. Using a 3-hydroxy-oxindole scaffold
enantioenriched spirooxindoles were prepared using a chiral
organocatalyst and further reaction steps led to the desired natural
product, as shown in Scheme 1 [48].2.1. Organocatalytic methods of synthesis e types of catalyst
2.1.1. Cinchona alkaloids
Cinchona alkaloids are natural products that have been widely
studied as asymmetric organocatalysts, as reviewed in the litera-
ture [49e52].
One example, reported by Sano et al., consisted of the use of this
type of catalyst for the asymmetric hydroxylation of oxindoles.
Using oxygen as a benign and environmentally friendly oxidant,
they prepared a library of 3-hydroxyoxindole derivatives in high
yields and enantioselectivities using a cinchonidine-based chiral-
phase transfer catalyst (C1 - Scheme 2) in the presence of a base
(KOH) [53]. Liao et al. applied a different hydroxylating agent (ar-
omatic oximes) for the production of enantioenriched 3,3-
disubstituted oxindoles in the presence of K2CO3 and the
cinchona alkaloid derivative C2 (Scheme 2) under mild conditions
[54].
Chauhan et al. prepared a library of 3-indole-3-
hydroxyoxindoles using a highly enantioselective Friedel-Crafts-
type addition of indole to isatin, in the presence of catalyst C3 e
Scheme 3 a) [55]. A similar library was prepared using the same
type of reaction with a slightly higher catalyst loading (20mol%
compared to 15mol% in the previous) and in a different solvent
(1,4-dioxane instead of THF) [56] (catalyst C4 e (Scheme 3 b)). Kaur
Fig. 1. Relevant bioactive compounds bearing the chiral 3-hydroxyoxindole structural motif.
Scheme 1. Total synthesis of maremycin A via enantioselective spirooxindole formation.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4929et al. used catalyst C5 (10mol%) for the preparation of 3-aryl-3-
hydroxy-2-oxindoles. They reported two libraries of compounds
using this cinchonidine-thiourea organocatalyst, one with the
addition of 1-naphthols, the other with the addition of phenols to
isatin derivatives (Scheme 3 c) and d)) [57,58]. The enantioselective
Friedel-Crafts alkylation of isatin derivatives and 1-naphthols was
also studied byWu et al., using the organocatalyst C6 (Scheme 3 e)).The authors also mentioned that the presence of a substituent with
a lone pair of electrons (such as 4-MeO or Cl) in the 1-naphthol
moiety of the 3-(naphthalene-2-yl)-3-hydroxy-2-oxindoles, could
lead to a spontaneous dehydration process, with formation of a
double bond [59].
Using N-protected isatin derivatives as starting materials and
reacting them with acrylates via a Morita-Baylis-Hillman reaction,
Scheme 2. Hydroxylation reactions using cinchona alkaloid-based chiral catalysts.
Scheme 3. Friedel-Crafts reactions using cinchona alkaloid-based asymmetric catalysts.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574930Guan et al. synthesized a library of twenty two 3-substituted-3-
hydroxyoxindole derivatives using catalyst C7 (Scheme 4 a);
10mol%), the products were obtained with moderate to excellent
yields and very good enantioselectivities [60]. Similar results were
achieved with the same catalyst by Zhoung et al., and their studies
showed that the C60-OH group participates in an intramolecular
proton relay process, hence facilitating the proton transfer step of
the catalytic process (Scheme 4 b) [61]. The same catalyst wasemployed in the reaction between isatin derivatives (and N-pro-
tected isatin derivatives) with acrolein as the nucleophile with
excellent results (Scheme 4 c) [62]. In another example, the same
catalyst C7 (b-isocupreidine) was employed in the asymmetric re-
action between N-protected isatin derivatives andmaleimides with
very good results (Scheme 4 d) [63].
In order to expand the scaffold diversity of this type of com-
pound, a similar approachwas reported recently, applying the same
Scheme 4. Morita-Baylis-Hillman reactions using a cinchona alkaloid-based asymmetric catalyst.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4931organocatalyst, and using 7-azaisatin derivatives as the starting
material (Scheme 5) [64]. It was found that 7-azaisatins showed
better reactivity as electrophiles than the analogous isatins,
affording the corresponding 3-hydroxy-7-aza-2-oxindole de-
rivatives in moderate to good yields and good enantioselectivities
[64].
The enantioselective aldol reaction is a powerful method for the
introduction of CeC bonds for the synthesis of enantiopure com-
pounds. A quinidine-thiourea catalyst (C8 e Scheme 6 a) e 10mol
%) was used to prepare 3-alkyl-3-hydroxyoxindole derivatives in
very good to excellent yields and enantioselectivities [65]. Simi-
larly, a cinchonidine-based urea catalyst (C9 e Scheme 6 b) e
20mol%) was applied with the objective of reacting isatin with
several unactivated ketones, resulting in the formation of 3-
substituted-3-hydroxyoxindole derivatives (24 examples) in high
yields and enantioselectivities [66]. In another example, the same
kind of reactionwas explored, this time in the preparation of 3-(2H-
chromen-2-one)-3-hydroxyoxindole derivatives, using isatin and
3-acetyl-2H-chromen-2-ones as starting materials and a quinidine-
urea bifunctional catalyst (C10 e Scheme 6 c)) [67]. Aldol adducts
were also synthesized in moderate to good yields and enantiose-
lectivities using isatin derivatives and a,b-unsaturated ketones as
starting materials, in the presence of the quinidine-thiourea orga-
nocatalyst C8 and its epimer C11 (Scheme 6 d)) [68].
The organocatalyst C8 (Scheme 6) was also applied in the
decarboxylative aldol addition of trifluoromethyl a-fluorinated
gem-diols to N-benzyl isatin derivatives, with the desired products
being obtained in almost quantitative yields and high enantiose-
lectivities, showing the versatility of this organocatalyst in the
synthesis of chiral fluorinated molecules (Scheme 7) [69].
In another example, a regioselective-reversed asymmetric aldol
reaction was reported, using a cinchonidine-thiourea bifunctional
organocatalyst (C5 e Scheme 8 a)). The aldol adducts were pre-
pared from the reaction between isatin derivatives and 1,3-Scheme 5. Morita-Baylis-Hillman reaction using 7-azaisatins as sudicarbonyl compounds, in moderate to high yields and enantiose-
lectivities [70]. The same catalyst was applied in the decarbox-
ylative addition of b-ketoacids to N-protected isatin derivatives
with very good yields and enantioselectivities (Scheme 8 b)) [71].
The catalyst 9-amino-(9-deoxy)-epi-cinchonidine and its
pseudo-enantiomer (10mol%; catalysts C12 and C13 e Scheme 9)
were applied in the asymmetric direct aldol reaction of isatin de-
rivatives with pyruvic aldehyde dimethyl acetal, using trichloro-
acetic acid (TCA) as additive, providing both enantiomers of the 3-
hydroxy-3-substituted-oxindole. It was catalyst C12 that afforded
the R-enantiomer, while the S-enantiomer was obtained using
catalyst C13, with very good to excellent yields and enantiomeric
purities [72].
A different approach was used by Hara et al., using a
squaramide-quinine catalyst (C14 e Scheme 10) to promote a
decarboxylative aldol reaction of isatin with malonic acid half-
thioesters. Both high yields and high enantioselectivities were
achieved, although the enantioselectivity was highly dependent on
the catalyst load and on the starting material substitution pattern
[73].
Cinchona alkaloids were also tested to perform enantioselective
phospho-aldol reactions between diphenyl phosphites and N-
alkylated isatin derivatives. The best results were achieved using
quinine as the organocatalyst (C15 - Scheme 11) and the final 3-
hydroxy disubstituted products were obtained in good to excel-
lent yields and low to moderate enantioselectivities. The reaction
was complete in one hour when 20mol% of catalyst was used [74].
The nitroaldol reaction, also known as the Henry reaction, in-
volves the use of nitroalkanes (e.g. nitromethane). Li et al. [75]. used
this reaction with isatin derivatives in the presence of catalyst C3
(10mol%), a library of 3-hydroxy-3-nitromethyloxindole de-
rivatives was obtained, with the C60-OH group and the quinuclidine
scaffold of the catalyst playing a major role in the asymmetric in-
duction of the reaction (Scheme 12 a)). That same year, anotherbstrates and a cinchona alkaloid-based asymmetric catalyst.
Scheme 6. Aldol reactions using isatin as substrates and cinchona alkaloid-based asymmetric catalysts.
Scheme 7. Aldol addition of trifluoromethyl a-fluorinated gem-diols to N-benzyl isatins.
Scheme 8. Organocatalyst C5 applied in different aldol reactions.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574932
Scheme 9. Direct aldol reaction of pyruvic aldehyde dimethyl acetal with isatin derivatives.
Scheme 10. Decarboxylative aldol reaction of isatin with malonic acid half-thioesters.
Scheme 11. Phospho-aldol reaction of isatin derivatives with diphenyl phosphites.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4933group reported the study of the Henry reaction using the same type
of reactants, however they applied a different catalyst (the bis-
cinchona alkaloid C16 - Scheme 12 b)). The use of a bis-cinchona
alkaloid as the organocatalyst allowed not only a reduction of the
catalyst loading (to 4mol%, which can be considered a low catalyst
load in the field of organocatalysis where 20mol% loading is
generally the norm)), but also a remarkable reduction of the reac-
tion time (from 4 to 5 days to< 14 h) [76]. Another quinidine-based
organocatalyst (C17 e Scheme 12 c)) was also reported for the
nitroaldol reaction with isatin derivatives [77].
Recently, an example of the asymmetric organocatalytic Wittig
[2,3]-rearrangement of oxindoles was reported. Using organo-
catalyst C14 (20mol%), 3-cinnamyloxyoxindole derivatives were
converted to 3-substituted-3-hydroxyoxindoles in very high yields
and enantioselectivities. Despite the low diastereoselectivity of the
reaction, the isomers could be separated by chromatography,
allowing their isolation and characterization (Scheme 13) [78].2.1.2. Urea and thiourea derivatives
In the examples previously mentioned, several of the organo-
catalysts were based on bifunctional cinchona alkaloid-(thio)urea
structures (catalysts C5, C6 and C8eC11).
However, instead of cinchona alkaloids, other amines can be
combined with the (thio)urea scaffold to develop efficient orga-
nocatalysts, as can be found in several review publications [79e82].
This family of catalysts has been employed in the synthesis of chiral
3-hydroxy-oxindole derivatives.
In one example, reported by Retini et al., the reduced form of
isatin dioxindole and dioxindole derivatives were converted to 3-
substituted-3-hydroxy-oxindoles through a 1,3-addition to nitro-
alkenes. On using catalyst C18 (20mol%) the desired products (14
examples) were obtained with moderate to very good yields and
enantiomeric excesses (Scheme 14) [83].
This family of catalysts has also been useful in different aldol
reactions. Thiourea functionalized organocatalysts C19 (Scheme 15
a)) promoted a highly efficient enantioselective direct vinylogous
Scheme 12. Asymmetric Henry reaction of isatin derivatives with nitromethane.
Scheme 13. Enantioselective organocatalytic [2,3]-rearrangement of oxindoles.
Scheme 14. 1,4-addition of dioxindole derivatives to nitroalkenes.
Scheme 15. Aldol reactions of isatin derivatives with ketones using thiourea-based organocatalysts.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574934
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4935aldol reaction involving isatin derivatives and allyl ketones [84].
Zhao et al. reported the development of axially unfixed biaryl-(thio)
urea bifunctional catalysts to allow aldol reactions to be performed
using water as solvent, and therefore it is an interesting green and
safe approach. The best results were achieved with catalyst C20
(Scheme 15 b) e 15mol%) and the resulting 3-alkyl-3-hydroxy-
oxindole derivatives were delivered, with various chemical yields
and enantioselectivities [85].
Organocatalyst C21 (Scheme 16 e 10mol%) gave moderate to
good yields and stereocontrol in the synthesis of chiral 3-hydroxy-
3-substituted-oxindole derivatives via an asymmetric Mannich
reaction between 3-hydroxy-oxindoles and amidosulfones,
creating 2 vicinal stereocenters [86].
Binaphthyl-based catalysts have become a versatile tool in
asymmetric catalysis over the past decades, with their axial
chirality playing a major role on reaction stereocontrol [87,88]. For
this reason, the study of bifunctional binaphthyl-(thio)urea orga-
nocatalysts appeared as a challenging field for several research
groups. Two examples of binaphthyl-bis(thio)urea catalysts in the
asymmetric synthesis of 3-hydroxy-oxindole derivatives have been
reported. Catalyst C22 (Scheme 17 a)) was studied for a Morita-
Baylis-Hillman reaction between a,b-unsaturated g-butyrolactam
and isatin derivatives. However, even in the presence of high
catalyst loading (100mol%) and in the presence of DABCO (1,4-
diazabicyclo[2.2.2]octane), the enantioselectivity values were
moderate (up to 78% ee) [89]. Better stereocontrol was achieved
with catalyst C23 (Scheme 17 b)) in the reaction of isatin derivatives
and formaldehyde N-tert-butyl hydrazine, with the resulting chiral
3-hydroxy-3-substituted-oxindole derivatives presenting enantio-
selectivities of up to 99% ee with good to excellent yields [90].2.1.3. Proline derivatives
Proline, a chiral amino acid, was shown to be an efficient catalyst
in several types of reactions, with the advantages that it is inex-
pensive and easily available in both enantiomeric forms. Several
publications can be found testifying to the versatility of proline-
derivatives as asymmetric organocatalysts [91e95].
The proline stereocenter in position 2 of the pyrrolidine het-
erocycle inspired the creation of new asymmetric catalysts. One
example was the use of (S)-pyrrolidine tetrazole C24 (Scheme 18 a)
e 15mol%), in the asymmetric crossed-aldol reaction of aldehydes
with isatin derivatives. Using water and H3PO4 as additives, chiral
3-substituted-3-hydroxy-oxindole derivatives (12 examples)
bearing two vicinal stereogenic centers were prepared with mod-
erate to good yields and enantioselectivities [96]. A 4-
hydroxydiarylprolinol catalyst C25 (Scheme 18 b) - 20mol%),
could promote the aldol reaction of acetaldehyde with different
isatin derivatives to achieve a library of 3-substituted-3-hydroxy-
oxindole derivatives, with no need for additives, and inmoderate to
high yields and good enantioselectivities. Two of the products
prepared were further used to synthesize four different natural
products with interesting biological activities: (R)-Scheme 16. Asymmetric Mannich reaction of 3-hydconvolutamydines B and E (Scheme 19), ()-donaxaridine and (R)-
chimonamidine [97].
Convolutamydine Awhich is isolated from the marine bryozoan
species Amathia convolute, is another very interesting scaffold in
Medicinal Chemistry. It presents a wide range of biological activ-
ities, including antitumor (HL-60 human pro-myelocytic leukemia
cells), antinociceptive and anti-inflammatory properties. Several
groups already reported the asymmetric synthesis of both enan-
tiomers of this molecule, using different organocatalysts, as sum-
marized in Scheme 20 [98e101].
Several convolutamydine A synthetic derivatives described in
the literature have demonstrated antinociceptive activity in animal
models. The synthetic methods were not enantioselective so the
results reported are only for racemic mixtures. Nevertheless, these
findings have shown that these compounds are active after oral
administration and that they can act in different pain mechanisms
and pathways, showing their potential use as drug candidates in
pain treatment [102,103].
(R)-convolutamydine A and seven derivatives were synthesized
by Hara et al. using a recyclable catalyst. Briefly, catalyst C28
(Scheme 21 a)) was entrapped in Montmorillonite by an ion-
exchange reaction. The asymmetric reactions not only could pro-
vide the desired chiral 3-substituted-3-hydroxy-oxindoles from the
reaction between isatin derivatives and acetone (or acetaldehyde)
in high yields and stereocontrol, but also could be recycled without
significant changes in the reaction outcome [104]. The same type of
reaction between isatin derivatives and acetone was explored by
Pearson et al. with moderate yields and moderate to good enan-
tiomeric excesses, but this time using an N-prolinylanthranilamide
pseudopeptide C29 as organocatalysts (Scheme 21 b) e 10mol%)
[105].
An enantioselective vinylogous aldol reaction of isatin de-
rivatives with a-branched enals was promoted using catalyst C30
(Scheme 22 e 10mol%) with the additive 2,6-bis(trifluoromethyl)
benzoic acid. The chiral 3-(a-branched-a,b-unsaturated-aldehyde)-
3-hydroxy-oxindole derivatives were obtained with moderate to
good yields and stereoselectivity [106].
The aldol reaction between isatin derivatives and 2,2-dimethyl-
1,3-dioxan-5-one was studied using the pseudopeptide organo-
catalyst C31 (Scheme 23) with the additive H3PO4, in moderate
yields and moderate to good enantiomeric excesses. One of the
obtained products achieved could be applied for the synthesis of
TMC-95A (Fig. 1) [107], a relevant biologically active compound
with reversible proteasome inhibition activity, and therefore
studied for its potential clinical application as an anticancer agent
[108,109].
The bifunctional proline-thiourea organocatalysts C32 (Scheme
24) catalyzed an asymmetric decarboxylative cyanomethylation of
isatin derivatives with cyanoacetic acid, with a catalyst loading of
just 5mol%. The chiral 3-cyanomethylene-3-hydroxy-oxindole de-
rivatives resultant from the reaction presented overall good enan-
tioselectivities, with moderate yields [110].roxyoxindole derivatives with amidosulfones.
Scheme 17. Use of bi-naphthyl-bis(thio)urea organocatalysts for the synthesis of chiral 3-hydroxy-3-substituted oxindole derivatives.
Scheme 18. Asymmetric aldol reaction of isatin derivatives with aldehydes using proline-inspired organocatalysts.
Scheme 19. Synthesis of chiral natural products (R)-convolutamydine E and B.
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Scheme 20. Asymmetric catalytic synthesis of Convolutamydine A.
Scheme 21. Asymmetric organocatalytic aldol reaction of isatin derivatives with acetone.
Scheme 22. Asymmetric vinylogous aldolization using organocatalyst C30.
Scheme 23. Asymmetric aldol reaction between isatin derivatives and 2,2-dimethyl-1,3-dioxan-5-one.
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Scheme 24. Enantioselective decarboxylative cyanomethylation using a bifunctional thiourea-proline based organocatalyst.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e495749382.1.4. Squaramide and phosphine derivatives
Squaramides, four-membered rings derived from squaric acid,
have significant interest in catalysis due to their ability to form up
to four hydrogen bonds. The addition of this moiety to chiral scaf-
folds is a highly desirable way to build new asymmetric catalysts.
Catalyst C14 (Scheme 10) is a good example, in which the squar-
amide ring was combined with a cinchona alkaloid, to achieve a
more efficient stereocontrol. The properties of squaramide-based
catalysts have already been explored in several publications
[111e114].
Phosphines bearing chiral skeletons are well established ligands
for asymmetric catalysis [115e117]. Qian et al. developed an effec-
tive catalyst combining these two scaffolds (catalyst C33 e Scheme
25 a)). Catalyst C33 (2mol%) could effectively catalyze a Morita-
Baylis-Hillman enantioselective synthesis of 3-hydroxy-3-
substituted-oxindole derivatives, using isatins as electrophiles.
The products were obtained in good to excellent yields and enan-
tioselectivities [118]. The same type of reaction with catalyst C34
(Scheme 25 b) e 5mol%) was studied by Dong et al., and gave
similar results [119]. These two examples illustrate the efficiency of
squaramide-phosphine organocatalysts, namely as regards the low
catalyst loading compared to other organocatalysts.
As shown for catalysts C22 and C23 (Scheme 17), the incorpo-
ration of axial chirality in organocatalysts, by using a binaphthyl
moiety, can improve considerably the enantioselectivity of an
asymmetric process. Catalyst C35 (Scheme 26) shows that a
binaphthyl-squaramide catalyst can create high levels of stereo-
control at very low catalyst loading (1mol%) and are more effective
than the corresponding binaphthyl-thiourea or cinchona alkaloid-
thiourea organocatalysts. In fact, catalyst C35 produced a library
of 19 chiral 3-hydroxy-3-phenacyloxindoles via decarboxylative
aldol addition of b-ketoacids to isatins with overall good yieldsScheme 25. Enantioselective Morita-Baylis-Hillman rea[120].
2.1.5. Diamines
The presence of amine groups is crucial for many catalytic
processes, as already reported in this work (e.g., with the cinchona
alkaloids). For this reason, the use of small-molecule chiral amines
has become an interesting research topic, both as bona fide cata-
lysts and as ligands.
Raj et al. reported the synthesis of chiral 3-cycloalkanone-3-
hydroxy-oxindole derivatives, using a primary-tertiary diamine
C36 (Scheme 27) with trifluoroacetic acid (TFA). Isatin derivatives
reacted with cyclohexanone in water medium and provided good
to excellent enantioselectivities and overall good yields. Among the
products of the reaction, compound (S)-3-hydroxy-3-((R)-2-
oxocyclohexyl)indolin-2-one is very interesting, since it presents
potential biological activity as an anticonvulsant agent, since it acts
as an antagonist for the biological process that lead to maximal
electroshock seizures (anti-MES) [121,122].
Liu et al. performed aldol reactions between isatin derivatives
and different ketones using 1,2-diaminohexane catalyst C37
(Scheme 28 a) e 20mol%) and hexanedioic acid (HDA) as co-
catalyst, with the best results being achieved with cyclic ketones
(up to 99% ee and 90% yield) [123]. A remarkably environmentally
benign procedure for “in water” aldol reaction of isatins with
cyclohexanone and acetone was developed by Kumar et al. The
simple primary-tertiary diamine C38 (Scheme 28 b)) proved to be
efficient at 1mol% catalyst loading, using 2,4-dinitrophenol (DNP)
as additive to achieve chiral 3-hydroxy-3-substituted oxindole
derivatives with good yields and enantioselectivities [124].
2.1.6. Miscellaneous
Carbohydrates, especially aminosugar-derivatives, surfaced overction using squarimide-phosphine organocatalysts.
Scheme 26. Asymmetric decarboxylative aldol addition of b-ketoacids to isatin derivatives using a binaphthyl-squaramide organocatalyst.
Scheme 27. Enantioselective synthesis of 3-cycloalkanone-3-hydroxy-2-oxindole derivatives.
Scheme 28. Enantioselective aldol reaction of isatin derivatives and ketones.
Scheme 29. Asymmetric aldol reaction using carbohydrate-derived organocatalysts.
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recently reviewed in the literature [125]. Shen et al. reported an
asymmetric aldol reaction between isatin derivatives and different
ketones, using organocatalysts C39 (Scheme 29 a) e 10mol%).
Although the carbohydrate-derived alcohol could afford the desired
3-hydroxy-3-substituted oxindole derivatives in high yields, thestereocontrol was quite limited (up to 75% ee) [126]. In another
recent example, which was a greener approach, chitosan C40
(Scheme 29 b) e 10mol%), in the form of aerogel, was used as the
catalyst for an asymmetric aldol reaction of isatin derivatives with
hydroxyacetone (or methoxyacetone). 2,5-Dihydroxybenzoic acid
was used as the additive and water as solvent. The desired chiral 3-
Scheme 30. a-Hydroxylation of 3-substituted-oxindole derivatives with molecular oxygen.
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and chemoselectivities under these environmentally benign con-
ditions [127].
Pentanidium-derived catalysts have also been described as
valuable for asymmetric reactions, namely phase-transfer catalysis
[128]. The use of this type of catalyst was reported in the successful
enantioselective a-hydroxylation of 3-substituted-oxindoles using
the inexpensive and green reagent, molecular oxygen. In fact,
catalyst C41 (Scheme 30 e 5mol%) afforded chiral 3-hydroxy-3-
substituted-oxindole derivatives with excellent enantioselectiv-
ities, via formation of the hydroperoxide oxindole followed by its
kinetic resolution to the hydroxyl-derivative [129].
The use of chiral sulfonamides in asymmetric catalysis has also
been reported for a range of different reactions [130e132].
Recently, the catalyst C42 (Scheme 31 - 20mol%), was used to
prepare 3-cycloalkanone-3-hydroxy-2-oxindole derivatives in high
yields and moderate to good enantioselectivities under neat con-
ditions at room temperature [133].
2.2. Transition-metal catalysis
The use of transition metals in catalysis, and particularly in
asymmetric catalysis, has been explored and reviewed in several
fields [134e140], including their application for the functionaliza-
tion of the 3-position of the oxindole scaffold [141,142]. To sys-
tematically review this topic, the examples will be organized
according to the periodic table periods.
2.2.1. Period 4 e Sc, Ni, Cu
Asymmetric catalytic synthesis of substituted 3-hydroxy-oxin-
dole derivatives using scandium (III) complexes is very desirable,
since these are among the few catalytic systems that do not require
the use of N-protected isatin derivatives. Franz's group exploredScheme 31. Aldol reaction using an aminothis Lewis acid on different occasions. First, they promoted the
monoaddition of indole and arene nucleophiles to isatins (indium
(III) complexes also proved to be efficient, but scandium (III) pro-
vided higher levels of stereocontrol when different nucleophiles
were tested), using 5mol% loading of the catalyst (Scheme 32 a))
[143]. Then, they further explored the enantioselective allylation of
isatins (including N-substituted isatins) using different allylsilanes,
also achieving high yields and enantioselectivities (even when
decreasing the catalyst loading to 0.05mol%, even though the re-
action time was extended under these conditions) (Scheme 32 b))
[144]. The same group further explored an asymmetric [3 þ 2]
annulation of allylsilanes with isatins to obtain spirooxindole de-
rivatives [145]. In all the cases, the best results were achieved using
(3aS,8aR)-indapybox (L1) as the chiral ligand. Indeed, oxazoline-
based chiral ligands are very versatile in asymmetric catalysis
with transition metals [146], as we demonstrate using further ex-
amples in this report.
The decarboxylative addition of malonic acid to different isa-
tins was reported by Gao et al., using nickel (II) as the metal
catalyst and L2 (Scheme 33) as the chiral ligand. The 2-(3-
hydroxy-2-oxoindolin-3-yl)acetic acid derivatives obtained from
this reaction presented moderate to good yields and enantiose-
lectivities [147].
In the first report on enantioselective synthesis of SM-130686,
an orally active growth hormone secretagogue [148], Tomita et al.
developed a different approach, since the desired product presents
a trifluoromethyl substituent at C4 of the oxindole scaffold and
therefore makes access to the C3 position of the oxindole difficult,
hampering formation of the quaternary stereogenic center. For this
reason, they performed a copper catalyzed (Cu(I)F) enantioselective
intramolecular arylation of arylboronate containing a-ketoamides,
using the chiral ligand L3 (Scheme 34) and this gave very satis-
factory yields and stereocontrol [149]. The (S)-enantiomer is theacid sulphonamide as organocatalyst.
Scheme 32. Scandium-catalyzed synthesis of chiral 3-hydroxy-3-substituted oxindole derivatives.
Scheme 33. Nickel-catalyzed asymmetric decarboxylative addition of malonic acid and isatin derivatives.
Scheme 34. Copper-catalyzed enantioselective intramolecular arylation.
Scheme 35. Key-asymmetric synthetic step for the synthesis of bioactive SM-130686 (BOM e benzyloxymethyl group).
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Scheme 36. Copper-catalyzed asymmetric synthesis of 3-hydroxy-oxindoles.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574942more biologically relevant enantiopode, and the asymmetric cata-
lytic step, as well as the final structure of SM-130686 are shown in
Scheme 35.
The synthesis of 3-aryl-3-hydroxy-oxindole derivatives has also
been carried out using copper (CuCl) and an N-heterocyclic carbene
ligand L4 (Scheme 36 a)), and were formed with moderate to good
yields and enantioselectivities [150].
The asymmetric addition of acetonitrile to isatin derivatives by
CeH activationwas also studied using copper (II) (Cu(OTf)2) and the
fluorous bisoxazoline ligand L5 (Scheme 36 b)), but the product
was obtained in low to moderate yields although the best enan-
tiomeric excess achieved was 92% ee [151]. The same authors
applied a similar ligand L6 (Scheme 36 c)) with Cu(OAc)2, to pro-
mote an a-hydrophosphonylation of isatin derivatives. The reaction
gave moderate to good yields and enantioselectivities of the
desired chiral a-oxindole-a-hydroxyphosphonates [152].
The Friedel-Crafts alkylation of pyrrole with isatins was studied
by Li et al. for both protected and unprotected isatins. The catalyst
system consisted in CuBr2, chiral ligand L7 (Scheme 37) and hex-
afluoroisopropanol (HFIP) as additive. The authors reported that
the addition of HFIP allows the formation of a key hydrogen bond
between the isatin NH and the catalyst, due to its weak Brønsted
acidity. For N-protected isatins, a one-step reactionwas carried out,
and it gave excellent yields and enantioselectivities. Similar results
were achieved with N-unprotected isatins using the same chiral
catalyst system, a two-step reaction pathway was identified, that
consisted first of a Henry reaction, followed by a retro-HenryScheme 37. Asymmetric catalytic Friedel-Cprocess [153].
The enantioselective oxygen atom transfer from an oxaziridine
to different 3-aryl-oxindole derivatives was reported by Naganawa
et al. [154]. The best results were achieved using Cu(OAc)2 and
ligand L8 (Scheme 38) as the chiral catalyst, with good yields and
very good enantioselectivities for the 3-aryl-3-hydroxy-oxindole
derivatives obtained [154].
Recently, Xu et al. established a protocol for the asymmetric
synthesis of 3-alkynyl-3-hydroxy-oxindole derivatives, from isatin
and terminal alkynes. The catalyst was formed by CuI and chiral
phosphine ligand L9 (Scheme 39), and the desired products were
achieved in good to excellent yields and stereocontrol (up to 94%
ee) [155].2.2.2. Period 5 e Ru, Rh, Pd, In, Sn
The synthesis of chiral 3-aryl-3-hydroxy-oxindoles using a
ruthenium-catalyzed arylboronic acid addition to N-protected isa-
tins was described by Yamamoto et al. [140]. To perform this task,
the authors used a chiral O-linked C2-symmetric bidentate phos-
phoramidite ((R,R)-Me-BIPAM) L10 (Scheme 40) as the ligand
(2.2mol%) and RuCl2(PPh3)3 (2mol%), in the presence of KF. The
desired products were obtained in excellent yields and good
enantioselectivities [156].
Gui et al. reported the same type of addition, but this time with
N-unprotected isatin derivatives, using rhodium (I). The catalyst
complex used consisted of [Rh(C2H4)2Cl2] (2mol%) and chiral
sulfoxide phosphine L11 (Scheme 41 a) e 4.8mol%) and the final 3-rafts alkylation of pyrrole with isatins.
Scheme 38. Enantioselective oxygen transfer to 3-aromatic-oxindole derivatives.
Scheme 39. Copper-catalyzed asymmetric addition of terminal alkynes to isatin derivatives.
Scheme 40. Ruthenium-catalyzed asymmetric addition of arylboronic acids to isatin derivatives.
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excellent yields and enantioselectivities [157]. The same reaction
was explored by Feng et al., using the same source of rhodium (I),
although with a higher catalyst loading (5mol%), and applying a
chiral sulfur-alkene ligand L12 (Scheme 41 b)). The complex was
applied to N-protected isatin derivatives only, but the results were
poorer than the ones previously described [158]. It must be noted
than when the introduced aryl group was a phenyl group the
configuration was established to be (R).
In our group, we also explored the use of rhodium (I) in asym-
metric catalysis to obtain compounds with potential biological ac-
tivity. The enantioselective addition of arylboronic acids to N-1,2,3-
triazole-isatin derivatives was reported, using (R)-BINAP ((R)-2,2-
bis(diphenylphosphino)-1,1-binaphthyl) as the chiral ligand (L13
e Scheme 42 e 6mol%) and Rh(acac) (C2H4)2 (3mol%). The
resulting N-(1,2,3-triazolemethyl)-3-hydroxy-3-aryl-oxindolederivatives where prepared with high levels of conversion and
enantioselectivities up to 97% ee [159]. The configuration of the
newly created quaternary center was not determined, but on the
basis of similar work could be tentatively assigned the (R)-
configuration.
We further explored this asymmetric catalytic system to obtain
the two enantiomers of the hit compound N-benzyl-3-hydroxy-3-
phenyloxindole and the synthesis of a library of related com-
pounds. Both the butyrylcholinesterase (BuChE) and acetylcholin-
esterase (AChE) inhibition of these compounds were screened. The
best result was achieved with 1-((1-benzylpiperidin-4-yl)-methyl)-
3-hydroxy-3-phenylindolin-2-one (the lead compound) (Scheme
43). While both enantiomers were more active towards the inhi-
bition of BuChE, the (S)-enantiomer proved to be more potent by
nine fold (IC50¼ 6.19 mM, while for the (R)-enantiomer value was
54 mM) [160].
Scheme 41. Rhodium-catalyzed asymmetric addition of arylboronic acids to isatin derivatives.
Scheme 42. Rhodium-catalyzed asymmetric addition of arylboronic acids to N-triazole-isatin derivatives.
Scheme 43. Asymmetric synthesis of 3-hydroxy-3-substituted-oxindole derivatives with cholinesterase inhibition activity.
Scheme 44. Palladium-catalyzed asymmetric intramolecular arylation of a-keto amides.
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catalyst in a wide variety of reactions, including asymmetric
catalysis [161e164]. Among these reactions, Shibasaki et al. re-
ported the use of palladium in an asymmetric intramolecular ary-
lation of a-keto amides. The catalyst [Pd(CH3CN)4](BF4)2/(R)-
difluorPhos (5mol%/6mol% - chiral ligand L14 e Scheme 44) could
generate chiral 3-hydroxy-2-oxindole derivatives in moderate togood yields and with very good stereocontrol (up to 95% ee) [165].
The asymmetric allylation of isatins with allylic alcohols was
reported by Qiao et al., using the catalyst [Pd(OAc)2]/L15 (Scheme
45 a); 5mol%/10mol%). This ligand proved to be the best of a
family of chiral spiro phosphoramidite ligands to access tertiary
homoallylic alcohols 3-allyl-3-hydroxy-oxindole derivatives.
Although the process resulted in very high yields, the
Scheme 45. Palladium-catalyzed asymmetric synthesis of 3-hydroxy-3-substituted oxindole derivatives.
Scheme 46. Catalytic asymmetric arylation of isatin derivatives with arylboronic acids using L17.
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alcohols were also the focus of the protocol developed by Aikawa
et al., who studied ene and aldol reactions of N-protected isatins
and isopropenyloxy(triisopropyl)-silane (for the ene reaction e
Scheme 45 b))/isopropenyloxy(tert-butyldimethyl)-silane (aldol
reaction e Scheme 45 c))/trimethylsilyl ketene thioacetal (aldol
reaction), using [Pd(SbF6)2] (10mol%) and the chiral ligand L16. The
chiral 3-hydroxy-3-substituted-oxindole derivatives were obtained
in high yields and with remarkable enantioselectivity in some cases
(>99% ee) [167].
The addition of arylboronic acids to N-substituted isatins
allowed the asymmetric catalytic synthesis of 3-aryl-3-hydroxy-
oxindole derivatives with moderate to good yields and enantiose-
lectivities. The catalyst consisted of a C2-symmetric cationic N-Scheme 47. Asymmetric allylation of 3-O-Boheterocyclic carbene-Pd2þ-diaqua complex, prepared from the
chiral ligand L17 (Scheme 46) [168].
Bis(oxazoline)-based ligands were tested in an asymmetric
allylation of N-substituted-3-O-Boc-oxindoles with allyl acetates.
The resulting 3-allyl-3-hydroxyoxindoles presented good enantio-
selectivities and diastereoselectivities (since a vicinal quaternary
carbon center is formed) when prepared in the presence of the
catalyst [Pd(h3-C3H5)Cl]2 (2.5mol%)/L18 (10mol%) with N,O- bis(-
trimethylsilyl)acetamide (BSA) and KOAc as additive (Scheme 47)
[169].
Indium (III) is another metal that has been applied in the
asymmetric synthesis of 3-hydroxy-3-substituted-oxindole de-
rivatives. Using ligand L1 with In(OTf)3 (10mol%), an effective
catalyst complex was obtained for the addition of pyrroles to N-c-oxindole derivatives using palladium.
Scheme 48. Indium catalyzed asymmetric addition of pyrroles to isatin derivatives.
Scheme 49. Asymmetric aldol reaction using a tin chiral catalyst.
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excellent yields and remarkable enantioselectivity (in many cases,
>99% ee was observed) (Scheme 48) [170].
A chiral (S)-BINOL-derived tin bromide C43 (Scheme 49) was
used, in the presence of sodium methoxide, to promote the aldol
reaction between isatin derivatives and 6-methoxy-1-tetralone-
derived alkenyl trichloroacetate (and trifluoroacetate) and other
alkenyl esters. The 3-alkylated-3-hydroxy-oxindole derivatives
were prepared in high yields and good enantioselectivities [171].2.2.3. Period 6 e Yb, Ir, Hg
Lanthanides have been widely described for their potential
application in asymmetric catalysis [172e174]. Among them,
ytterbium was applied in the enantioselective decarboxylative
addition of b-ketoacids to isatins. The use of N-substituted isatins
proved to be crucial for the reaction yield and enantioselectivity, in
the presence of the catalytic system Yb(OTf)3/L1. The resulting
chiral 1-benzyl-3-hydroxy-3-substituted-oxindole derivatives
were obtained in very good yields (88e95%) and moderate to
excellent enantioselectivities (65e98% ee) (Scheme 50) [175].
Iridium is a transition-metal from period 6 of the periodic table
that presents a wide range of applications in synthesis [176,177].
Itoh et al. reported the first asymmetric allylations (Scheme 51 a)),
crotylations (Scheme 51 b)) and prenylations (Scheme 51 c)) of N-
benzyl-isatin derivatives, using an isopropanol mediated transfer
hydrogenation, in the presence of the catalyst [Ir(cod)Cl]2 (2.5mol
%) and the ligand cth-(R)-p-phos L19 ((R)-(þ)-2,20,6,60-tetrame-
thoxy-4,40-bis(diphenylphosphino)-3,30-bipyridine - 5 mol%),
achieving moderate to good yields and good to excellentScheme 50. Decarboxylative addition of b-ketoacidenantioselectivities (up to 96% ee) [178].
Using the same iridium source but with a lower catalyst loading
(1mol%), in the presence of the chiral phosphoramidite ligand L20
(Scheme 52), Zhuang et al. described the first iridium catalytic
system for the asymmetric addition of arylboronic acids to N-pro-
tected isatin dertivatives, achieving excellent results, in both yields
and reaction stereocontrol [179].
A different approach was used by Yamamoto's group to prepare
3-hydroxy-3-substituted-oxindole derivatives with iridium. They
promoted an asymmetric intramolecular direct hydroarylation of
a-ketoamides using cationic iridium ([Ir(cod)2](BarF4)) and chiral
ligand L10, affording the desired products in high to excellent yields
and enantioselectivities (Scheme 53) [180]. Further studies indi-
cated that the turnover-limiting step in the catalytic cycle was the
carbonyl insertion step into the aryl-iridium bond [181].
Mercury based catalysts can also be used. However, the catalytic
system that combined both Hg and the (S)-enantiomer of L13 gave
the 3-hydroxy-3-substituted product with mediocre stereocontrol
(up to 63% ee) (Scheme 54) [182].3. 3-Amino-oxindole derivatives
3.1. Organocatalysis
3.1.1. Cinchona alkaloids
As is the case with chiral 3-hydroxyoxindole derivatives, a vast
number of 3-amino-oxindoles have been prepared via asymmetric
catalytic methods using cinchona alkaloids as catalysts.
Organocatalyst C16 was evaluated by two distinct researchs to isatin derivatives catalyzed by ytterbium.
Scheme 51. Allylation, crotylation and reverse prenylation of isatin derivatives.
Scheme 52. Iridium-asymmetric catalytic addition of arylboronic acids to isatin derivatives.
Scheme 53. Iridium-catalyzed asymmetric intramolecular direct hydroarylation of a-keto amides.
Scheme 54. Mercury-catalyzed asymmetric Sakurai-Hosomi allylation of isatin derivatives.
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cinchona alkaloid (10mol%) in the reaction between N-protected
oxindole derivatives and diethyl azodicarboxylate, with excellent
yields and enantioselectivities (Scheme 55 a)) [183]. On the other
hand, N-unprotected 3-amino-2-oxindole derivatives wereprepared using the same catalyst loading as Cheng et al., but this
time different dialkyl azodicarboxylates were evaluated, with dii-
sopropyl azodiacarboxylate being the most promising electrophilic
aminating reagent, as regards both yield and enantiomeric excess
(Scheme 55 b)) [184].
Scheme 55. Asymmetric organocatalytic a-amination using C16.
Scheme 56. Asymmetric organocatalytic a-amination using C44, C8 and C11.
Scheme 57. Asymmetric organocatalytic N-nitroso-aldol reaction using C45.
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C44, which required a lower catalyst load (5mol%) to prepare 3-
amino-3-arylsubstituted-oxindole derivatives, using di-tert-butyl
azodicarboxylate (Scheme 56 a)) [185]. The same amination re-
agent was applied in another study, where the quinine-derived
thiourea bifunctional catalyst C8 and its epimer C11 (10e30mol
%) was employed to promote the asymmetric a-amination of un-
protected 3-aryl. C11 could afford the opposite enantiomer as
desired, however it was slightly less reactive and enantioselective
than C8 (Scheme 56 b)) [186].
The cinchona catalyst C45 (10mol%) proved to be an efficient
catalyst for the asymmetric N-nitroso-aldol reaction between
different N-unprotected oxindole derivatives and nitrosobenzene
(Scheme 57) [187].
A very desirable route to obtain chiral 3-amino-3-substitutedoxindole derivatives is the direct nucleophilic reaction of the
respective ketimines. With this goal, Hara et al. reported a decar-
boxylative addition of malonic acid half-thioesters to ketimines,
and the best results were achieved with N-(8-quinolinesulfonyl)-9-
amino-9-deoxy-epi-cinchonidine C46 (Scheme 58 a) e 20mol%).
This proved to be an interesting approach as a key-step for the
synthesis of AG-041R (Scheme 59), a bioactive compound with
gastrin/cholecyctokinin-B receptor antagonist activity, which can
be applied as a cartilage defects repair agent [188e190]. Ketimines
were also used in the enantioselective synthesis of 3-
aminooxindoles, via addition of 1,3-dicarbonyl compounds, using
organocatalyst C8 (Scheme 58 b)) [191].
The catalyst C8 was also useful for the preparation of chiral 3-
amino-3-cyano-oxindole derivatives, through the nucleophilic
addition of trimethylsilyl cyanide to N-Boc protected ketimines
Scheme 58. Asymmetric reactions of ketimines with 1,3-dicarbonyl compounds.
Scheme 59. Key-step for the synthesis of bioactive compound AG-041R.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4949(Scheme 60 a)). This was the first reported enantioselective orga-
nocatalyzed Strecker reaction using this type of substrate as elec-
trophile and proved to be an efficient route [192]. Catalyst C5 was
applied in the hydrophosphonylation of ketimines giving chiral 3-
amino-3-substituted-oxindoles in moderate to good yields and
enantioselectivities (Scheme 60 b)) [193].
Organocatalyst C3 (20mol%) proved to be effective in theScheme 60. Asymmetric Strecker reaction (a) a
Scheme 61. Asymmetric organocatalytic aformation of chiral 3-amino-3-nitromethyloxindole derivatives,
which were formed via an aza-Henry reaction between ketimines
and nitroalkanes (Scheme 61) [194].
Morita-Baylis-Hillman carbonates of isatins underwent asym-
metric allylic amination with N-silyloxycarbamates using organo-
catalyst C47 (10mol%), and afforded chiral 3-amino-3-substituted-
oxindoles with good to excellent enantiomeric excesses and yields
(Scheme 62) [195].
In order to access a library of chiral 3-ethylacetate-substituted-
3-amino-2-oxindole derivatives, Zhao et al. developed an organo-
catalytic Mannich/denitration reaction. Catalyst C48 proved to be
the most efficient one to promote the addition of ethyl nitroacetate
to different N-Boc ketimines, affording the target compounds in
moderate to good yields and very good to excellent enantiose-
lectivity (Scheme 63 a)). This approach seems to be an interesting
alternative route to obtain the already mentioned bioactive com-
pound AG-041R [196]. Recently, new cinchona alkaloid-derived
phase-transfer catalysts were developed to perform asymmetric
nitro-Mannich reactions on isatin-derived N-Boc ketimines. The
quinine-urea bifunctional catalyst C49 (10mol%) afforded the
desired chiral 3-amino-3-nitroalkyloxindole derivatives with
excellent yields and very good enantiomeric excesses (Scheme
63 b)) [197].
Bao et al. reported the use of catalyst C14 to promote an asym-
metric Friedel-Crafts addition/fluorination sequence to synthesize
oxindole-pyrazolone hybrid compounds. The reaction between the
4-nonsubstituted pyrazolones and N-Boc ketimines derived fromnd hydrophosphonylation (b) of ketimines.
za-Henry reaction using catalyst C3.
Scheme 62. Asymmetric allylic amination of Morita-Baylis-Hillman carbonates of isatins.
Scheme 63. Asymmetric Mannich/denitration reaction (a) and nitro-Mannich reaction (b), using isatin-derived N-Boc ketimines as starting material.
Scheme 64. Asymmetric organocatalytic synthesis of oxindole-pyrazolone hybrids.
Scheme 65. Asymmetric hydroxyamination catalyzed by chiral bifunctional tertiary amine-thiourea organocatalysts.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574950
Scheme 66. Organocatalytic asymmetric Michael addition (a) and Mannich reaction (b), using bifunctional tertiary amine-thiourea organocatalysts.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4951isatin proceeded with excellent yields and enantioselectivities with
a catalyst loading as low as 0.5mol% (Scheme 64) [198].3.1.2. Thiourea derivatives
Organocatalyst C21 (20mol%) was effectively applied in the a-
hydroxyamination of N-unprotected 3-substituted-2-oxindoles
with nitrosobenzene. The chiral adducts generated by this
nitroso-aldol reaction presented good yields and enantioselectiv-
ities (Scheme 65 a)) [199] Jia et al. reported the same type of re-
action and created a library of 16 chiral 3-amino-3-substituted
oxindole compounds with moderate to good yields and enantio-
selectivity, using 20mol% of catalyst C50 (Scheme 65 b)) [200].
In another example, 3-monosubstituted 3-aminooxindoles were
used as starting material for an asymmetric Michael addition with
nitroolefins. The quaternary 3-amino-oxindoles obtained with
organocatalyst C51 (10mol%) contained contiguous stereocenters,
and were obtained in high yields with very good levels of diaster-
eoselectivity and enantioselectivity (Scheme 66 a)) [201].
Recently, 3-monosubstituted 3-amino-oxindole derivativesScheme 67. Organocatalytic asymmetric aza-Morita-Baylis-Hillman reaction using BINOL-
catalyst C54 (b).underwent asymmetric Mannich reaction with in situ generated N-
Boc-protected aldimines in the presence of catalyst C52. The
compounds obtained in this library (22 examples) were obtained in
high yield, diastereoselectivity and enantiomeric excess (Scheme
66 b)) [86].3.1.3. Squaramide and phosphine derivatives
An asymmetric aza-Morita-Baylis-Hillman reaction was cata-
lyzed by BINOL-phosphine-derived catalyst C53 (20mol%), using
isatin derived ketimines and methyl vinyl ketone as substrates. The
resulting chiral 3-amino-oxindole derivatives were obtained in
good to excellent enantioselectivities and overall good yields. It was
also noticed that the reaction required a shorter period (48 h), than
when compared to the b-isocupreidine organocatalysts (72 h)
(Scheme 67 a)) [202]. A similar approach was studied by Zhao et al.,
but using different acrylates as substrates and a phosphine-
squaramide-derived organocatalyst C54. Overall good stereo-
control and good to excellent yields were achieved using this
catalyst albeit with a remarkable loading of just 2mol% (Scheme 67phosphine organocatalysts C53 (a) and bifunctional phosphine-squaramide organo-
Scheme 68. Asymmetric organocatalytic synthesis of cyclic enaminone-based 3-amino-3-substituted-oxindole derivatives.
Scheme 69. Asymmetric organocatalytic synthesis of bioactive compounds using
organocatalyst C55.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574952b)) [203].
The chiral phosphoric acid-derived catalyst C55 (10mol%) was
successfully applied for the preparation of a library of cyclic
enaminone-based 3-substituted-3-amino-oxindole derivatives,
using molecular sieves (3Å) as additive (Scheme 68). The re-
searchers also demonstrated that the same system could be used in
a scale-up procedure. Also, the compound's cytotoxicity was
accessed. Both the racemic mixture and the isolated enantiomers
were screened with four different cancer cell lines (A549 e lung
cancer; 786-0 e kidney cancer; ECA109 e esophageal carcinoma;
BT474e Breast cancer). While the racemic mixtures did not present
relevant activities, the single enantiomers gave better results, with
the effect being dependent not only on the enantiomer, but also on
the cell line in question (i.e., in some cell lines, the (R)-enantiomer
was more active than the (S)-enantiomer, but in other cell lines the
inverse was seen). Examples of bioactive enantiomers are pre-
sented in Scheme 69 [204]. This in fact underlines the importance
of asymmetric synthesis procedures in medicinal chemistry.3.1.4. Triazolium salts
Triazolium salts have become important tools in asymmetric
catalysis [128,205,206]. Catalyst C56 was able to catalyze asym-
metric a-amination reactions of different hydroxylamines with N-
Boc-protected-3-phenyl-oxindole, at a catalyst loading of 5mol%.
The resulting a-aminocarbonyl compounds (3-phenyl-3-amino-
substituted- oxindole derivatives e 15 examples) presented
excellent enantioselectivities and moderate to very good yields(Scheme 70) [207]. Azolium salts, as well as N-heterocyclic carbene
compounds that originate azolium species during the catalytic cy-
cle, have also been applied in kinetic resolution experiments to
afford enantioenriched 3-hydroxy-3-substituted-oxindole de-
rivatives [208,209].3.2. Transition-metal catalysis
3.2.1. Period 4 e Sc, Fe, Ni
Chiral scandium complexes have been used by Feng's group to
promote asymmetric reactions with 3-substituted oxindole de-
rivatives. In one example, they reported an a-amination reaction
using Sc(OTf)3 and an N,N0-dioxide ligand L21 to catalyze the re-
action between 3-substituted-oxindole derivatives and different
azodicarboxylates. Depending on the substrate, they could reduce
the catalyst loading to 0.5mol% of Sc(OTf)3 and 0.75mol% of L21,
obtaining the 3-amine-3-substituted-oxindole derivatives with
good to excellent yields and enantioselectivities (Scheme 71 a))
[210]. Using the same chiral scandium complex, they further
expanded the scope of this catalyst to enantioselective hydrox-
yamination reactions of 3-substituted-oxindole derivatives with
nitrosoarenes. The resulting 3-hydroxyamine-3-substituted-oxin-
dole derivatives were obtained in high to excellent yields and
enantioselectivities showing, once again, the utility and versatility
of this scandium catalyst complex (Scheme 71 b)) [211].
Nickel has also been described by several groups for its ability to
participate in chiral complexes and in asymmetric catalysis. A great
example of the applicability of these complexes is the enantiose-
lectivity switch induced by the presence of homobimetallic or
monometallic Schiff base catalysis reported by Shibasaki's group.
Using chiral ligands L22 and L23 they could prepare homo-
bimetallic complexes and monometallic complexes, respectively.
Remarkably, using N-Boc-protected-3-substituted-oxindoles and
azodicarboxylates as starting materials, they observed that the
homobimetallic complex provided the (R)-enantiomer of the 3-
amino-3-substituted-oxindole derivatives (Scheme 72 a)) and the
monometallic complex resulted in the (S)-enantiomer (Scheme 72
b)) and, in both cases, excellent enantioselectivities and yields were
achieved [212].
In another example on the use of nickel in asymmetric catalysis,
Arai et al. reported the use of the complex between NiCl2 (5mol%)
with the chiral ligand (S,S)-diphenyldiamine-derived
bis(imidazolidine)-pyridine L24 (5.5mol%) to promote a nitro-
Mannich reaction. They verified that even under mild reaction
conditions, N-protected isatin-derived N-Boc ketimines could be
converted into chiral 3-amino-3-substituted-oxindole derivatives
with promising results (up to 99% yield and 95% ee) (Scheme 73)
[213].
Scheme 70. Direct catalytic asymmetric a-amination of N-Boc protected 3-phenyl-oxindole using triazolium salt C56.
Scheme 71. Catalytic asymmetric a-amination (a) and hydroxyamination (b) of oxindole derivatives using the scandium-L21 complex.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4953Recently, the synthesis of chiral 3-amino-3-substituted oxin-
doles was reported through the application of a chiral catalyst
complex Ni(dppp)Cl2/bis(oxazoline) ligand L25. In this study, the
substrates consisted of 3-bromo-3-substituted-oxindole de-
rivatives and anilines, and the final products were obtained in good
yields and enantioselectivity (Scheme 74) [214].3.2.2. Period 5 e Rh and Pd
While these metals are widely applied in the preparation of
chiral 3-hydroxy-oxindole derivatives, there are not many reports
on the use of metals from period 5 in the preparation of chiral 3-
amino-oxindole derivatives.
In one example, reported by Ren et al., the catalyst complex
formed between [Rh2(OAc)4] and compound C55, catalyzed an
aldol-type three component reaction between 3-diazo oxindole
derivatives, anilines and glyoxylates to obtain the chiral products in
moderate to excellent yields and enantioselectivities (Scheme 75)
[215].Recently, in our group, we presented the first asymmetric cat-
alytic arylation of isatin-derived ketimines with arylboronic acids
to obtain chiral 3-amino-3-aryl-oxindole derivatives. Using the
(S,S)-diene-type chiral ligand L26 [216], the best result was
observed, was 30% yield and 39% ee (Scheme 76) [217].
Tolstoy et al. reported a new synthetic route to prepare chiral 3-
amino-oxindole derivatives using palladium, via asymmetric
intramolecular arylation of a-ketimino amides. The catalyst system
was composed of [Pd(CH3CN)4](BF4)2 (5mol%) and L14 (10mol%).
The reaction's stereocontrol and yields were highly dependent on
the substituent pattern, ranging from 51e96% ee and 47e95% yield
(Scheme 77) [218].4. Final remarks
As shown in this report, significant progress has been achieved
in the asymmetric synthesis of chiral 3-hydroxy-3-substituted-
oxindole derivatives and 3-amino-3-substituted-oxindole
Scheme 72. Enantioselectivity switch performed by bimetallic versus monometallic nickel-chiral ligand complexes.
Scheme 73. Nickel-L24 complex catalyzed asymmetric nitro-Mannich reaction.
Scheme 74. Asymmetric catalytic amination reaction of 3-bromo-3-substituted-oxindole derivatives using nickel-L25.
Scheme 75. Brønsted-acid C55/rhodium (II) asymmetric catalytic three-component aldol-typre reaction.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e49574954
Scheme 76. (S,S)-diene-type chiral ligand/rhodium catalyzed asymmetric arylation of a ketamine with phenylboronic acid.
Scheme 77. Palladium/L14 asymmetric catalytic intramolecular arylation of a-ketoimino amides.
P. Brand~ao, A.J. Burke / Tetrahedron 74 (2018) 4927e4957 4955derivatives over the past decade. While metal/chiral ligand com-
plex catalysis still has the advantage of often requiring less catalyst
loading than that for organocatalysts, the recent advances in
organocatalysis have allowed researchers to decrease the required
organocatalyst loading, whilst maintaining the high levels of re-
action stereocontrol.
Asymmetric catalysis has proven to be an invaluable tool for the
synthesis of chiral bioactive compounds, with a wide range of
medicinally relevant applications. Moreover, there has been a
staggering increase in the number of publications on the asym-
metric catalytic synthesis of 3-hydroxy and 3-amino-oxindole de-
rivatives that are useful new scaffolds for providing key targets
with pharmacological activity.Acknowledgements
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